Recombinant multi-species NR2E3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NR2E3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This protein is part of a large family of nuclear receptor transcription factors involved in signaling pathways. Nuclear receptors have been shown to regulate pathways involved in embryonic development, as well as in maintenance of proper cell function in adults. Members of this family are characterized by discrete domains that function in DNA and ligand binding. This gene encodes a retinal nuclear receptor that is a ligand-dependent transcription factor. Defects in this gene are a cause of enhanced S cone syndrome. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
The Alternative Names of target: A930035N01Rik,ESCS,NR2E3,Nr2e3,Nuclear receptor subfamily 2 group E member 3,PNR,Photoreceptor-specific nuclear receptor,RNR,RP37,Retina-specific nuclear receptor,rd7
Go
to NR2E3 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP2976-Ag-1/ GM-Tg-hg-IP2976-Ag-2 | Human NR2E3 protein | Human |
| GM-Tg-rg-IP2976-Ag-1/ GM-Tg-rg-IP2976-Ag-2 | Rat NR2E3 protein | Rat |
| GM-Tg-mg-IP2976-Ag-1/ GM-Tg-mg-IP2976-Ag-2 | Mouse NR2E3 protein | Mouse |
| GM-Tg-cynog-IP2976-Ag-1/ GM-Tg-cynog-IP2976-Ag-2 | Cynomolgus/Rhesus macaque NR2E3 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP2976-Ag-1/ GM-Tg-felg-IP2976-Ag-2 | Feline NR2E3 protein | Feline |
| GM-Tg-cang-IP2976-Ag-1/ GM-Tg-cang-IP2976-Ag-2 | Canine NR2E3 protein | Canine |
| GM-Tg-bovg-IP2976-Ag-1/ GM-Tg-bovg-IP2976-Ag-2 | Bovine NR2E3 protein | Bovine |
| GM-Tg-equg-IP2976-Ag-1/ GM-Tg-equg-IP2976-Ag-2 | Equine NR2E3 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP2976-Ag-1/ GM-Tg-hg-IP2976-Ag-2;
GM-Tg-rg-IP2976-Ag-1/ GM-Tg-rg-IP2976-Ag-2;
GM-Tg-mg-IP2976-Ag-1/ GM-Tg-mg-IP2976-Ag-2; GM-Tg-cynog-IP2976-Ag-1/ GM-Tg-cynog-IP2976-Ag-2; GM-Tg-felg-IP2976-Ag-1/ GM-Tg-felg-IP2976-Ag-2; GM-Tg-cang-IP2976-Ag-1/ GM-Tg-cang-IP2976-Ag-2; GM-Tg-bovg-IP2976-Ag-1/ GM-Tg-bovg-IP2976-Ag-2; GM-Tg-equg-IP2976-Ag-1/ GM-Tg-equg-IP2976-Ag-2 |
| Products Name | NR2E3 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | NR2E3 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NR2E3 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.